Cantargia Q1 2023: Strong results with IL1RAP-high patients - Redeye

Redeye reviews Cantargia’s first quarter report. Since our last update (Q4 2022), important results have been published at the AACR meeting, demonstrating the superior efficacy of nadunolimab in pancreatic cancer patients with high levels of IL1RAP. The next step in the development of nadunolimab in pancreatic cancer will be a phase IIb study instead of the registrational Precision Promise. However, due to the longer development needed and other factors we lower our Base Case.

Länk till analysen i sin helhet: https://www.redeye.se/research/910867/cantargia-q1-2023-strong-results-with-il1rap-high-patients?utm_source=finwire&utm_medium=RSS